Reolysin: Completed Phase II enrollment

Oncolytics Biotech said the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) completed enrollment of 103 patients in an open-label, Canadian Phase II trial comparing IV Reolysin p...